Patents by Inventor Francesca Milletti

Francesca Milletti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190256929
    Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 22, 2019
    Inventors: Fabian BIRZELE, Wei-Yi CHENG, Mark D. DEMARIO, Fiona MACK, Francesca MILLETTI, William E. PIERCEALL
  • Publication number: 20190153538
    Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.
    Type: Application
    Filed: October 8, 2016
    Publication date: May 23, 2019
    Inventors: Wei-Yi CHENG, Mark D. DEMARIO, Fiona MACK, Francesca MILLETTI, William E. PIERCEALL
  • Publication number: 20180094030
    Abstract: The present invention relates to cell penetrating peptides and methods of identifying cell penetrating peptides based upon hydrophobicity and polarity.
    Type: Application
    Filed: June 16, 2017
    Publication date: April 5, 2018
    Inventor: Francesca Milletti
  • Publication number: 20170369529
    Abstract: Provided herein are cell penetrating peptides optionally including a cargo moiety linked thereto.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Inventor: Francesca Milletti
  • Patent number: 9409961
    Abstract: The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: August 9, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, Nader Fotouhi, Yi Han, Wajiha Khan, Francesca Milletti, Huifeng Niu
  • Publication number: 20160009772
    Abstract: The present invention comprises cell penetrating peptides that bind to interferon regulatory factor IRF5 and disrupt the IRF5 homo-dimerization and/or attenuate downstream signaling, and a method for screening peptides that inhibit IRF5. Generally, the cell penetrating peptides of the invention bind human interferon regulatory factor IRF5 (CPP-IRF5).
    Type: Application
    Filed: October 7, 2013
    Publication date: January 14, 2016
    Inventors: Julie Demartino, Nader Fotouhi, Ann Hoffman, Kuo-Sen Huang, Francesca Milletti, Sandip Panicker, Dinesh Srinivasan, Seng-Lai Tan
  • Publication number: 20150183827
    Abstract: The present invention relates to cell penetrating peptides and methods of identifying cell penetrating peptides based upon hydrophobicity and polarity.
    Type: Application
    Filed: June 24, 2013
    Publication date: July 2, 2015
    Inventor: Francesca Milletti
  • Publication number: 20150166621
    Abstract: The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 18, 2015
    Inventors: Waleed Danho, Nader Fotouhi, Yi Han, Wajiha Khan, Francesca Milletti, Huifeng Niu